Fernanda I. Arnaldez

机构：AstraZeneca (Netherlands), AstraZeneca (United States) · ORCID：0000-0003-1185-2498

发表论文 73 篇 · 总被引 998 次 · h-index 15

代表论文

• Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors (2024 · Journal for ImmunoTherapy of Cancer · 被引 27)
• Abstract 5736: AZD9592: An EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond (2023 · Cancer Research · 被引 27)
• EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors. (2023 · Journal of Clinical Oncology · 被引 19)
• LILRB2 blockade facilitates macrophage repolarization and enhances T cell-mediated antitumor immunity (2025 · Journal for ImmunoTherapy of Cancer · 被引 13)
• Abstract 5737: Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate (2023 · Cancer Research · 被引 10)
• Abstract 2961: AZD9592, an EGFR/cMET bispecific antibody-drug conjugate (ADC), demonstrates target-dependent efficacy in colorectal cancer (CRC) patient-derived xenograft (PDX) models (2025 · Cancer Research · 被引 3)